{
    "clinical_study": {
        "@rank": "117699", 
        "arm_group": {
            "arm_group_label": "Brexpiprazole", 
            "arm_group_type": "Experimental", 
            "description": "Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment\n      in patients with Major Depressive Disorder (MDD)"
        }, 
        "brief_title": "Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder", 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is judged to benefit from adjunctive treatment with brexpiprazole\n             according to the clinical opinion of the investigator.\n\n          -  The patient had MDD at entry in lead-in brexpiprazole studies, NCT01838681 / 14570A\n             or NCT01837797 / 14571A, diagnosed according to DSM-IV-TR\u2122.\n\n          -  The patient agrees to protocol-defined use of effective contraception.\n\n        Exclusion Criteria:\n\n          -  The patient has a disease or takes medication that could, in the investigator's\n             opinion, interfere with the assessments of safety, tolerability, or efficacy, or\n             interfere with the conduct or interpretation of the study.\n\n          -  The patient has been diagnosed with a psychiatric disorder other than MDD during the\n             lead-in studies NCT01838681 / 14570A or NCT01837797 / 14571A.\n\n          -  The patient, in the opinion of the investigator or according to C-SSRS, is at\n             significant risk of suicide.\n\n          -  The patient has any relevant medical history or current presence of systemic disease.\n\n          -  The patient has, at the Baseline Visit an abnormal ECG that is, in the investigator's\n             opinion, clinically significant.\n\n          -  The patient has a moderate or severe ongoing adverse event related to study\n             medication from the lead-in studies considered of potential safety risk by the\n             investigator.\n\n          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol\n             or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1184", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944969", 
            "org_study_id": "14767B", 
            "secondary_id": "2012-004169-42"
        }, 
        "intervention": {
            "arm_group_label": "Brexpiprazole", 
            "description": "Up to 3 mg/day, once daily dose, tablets, orally", 
            "intervention_name": "Brexpiprazole", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32806"
                }, 
                "name": "US008"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Estonia: The State Agency of Medicine", 
                "Finland: Finnish Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Slovakia: State Institute for Drug Control", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of adverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks and a 4-week safety follow up"
            }, 
            {
                "description": "Number of withdrawals", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "description": "Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944969"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Montgomery Aasberg Depression Rating Scale (MADRS) total score", 
                "measure": "Change in depressive symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "description": "Based on a pre-specified MADRS total score", 
                "measure": "Proportion of patients in remission", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "description": "Clinical Global Impression - Severity of Illness (CGI-S) score", 
                "measure": "Change in clinical global impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "description": "Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-(SF)) total score", 
                "measure": "Change in health-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "description": "EuroQoL 5 Dimensions 5L version (EQ-5D-5L) Visual Analogue Scale (VAS) score", 
                "measure": "Change in health-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}